In the labyrinthine world of American healthcare policy, few pieces of legislation have been as transformative—or as contentious—as the No Surprises Act (NSA). Designed to shield patients from the financial shock of “surprise” out-of-network medical bills, the law was hailed as a landmark victory for consumer protection. However, a recent analysis published in Health Affairs has ignited a firestorm of debate, suggesting that the federal Independent Dispute Resolution (IDR) process—the mechanism intended to resolve payment disagreements between insurers and providers—has quietly ballooned into a $22.4 billion administrative and financial burden.
For Richard Heller, MD, and Malea Reising, MS, of Radiology Partners, the nation’s largest filer of arbitration disputes under the NSA, this figure is not just a statistical estimate; it is an exercise in incomplete accounting. As stakeholders at the center of the IDR process, they argue that the Health Affairs analysis suffers from a fundamental flaw: it counts the costs of the arbitration process while willfully ignoring the billions in savings the NSA has generated for the healthcare system.
The Chronology of a Policy Shift
To understand the current tension, one must look back to the legislative intent of the No Surprises Act. Before its enactment, patients were frequently caught in the crossfire of “balance billing,” where insurers and medical providers could not agree on rates, leaving the patient responsible for the remaining balance.
- Pre-2022: The landscape was defined by high-stress billing disputes that placed the burden of cost on patients.
- January 1, 2022: The NSA took effect, mandating that patients be removed from billing disputes entirely. It established the IDR process, a "baseball-style" arbitration where both parties submit an offer, and an arbitrator selects one.
- 2023–2024: As the IDR process matured, a bottleneck emerged. The sheer volume of disputes—driven by insurer behavior and disagreements over the Qualifying Payment Amount (QPA)—led to massive administrative backlogs.
- 2024–2025: Academic and policy researchers began auditing the “cost” of this system, leading to the current Health Affairs report that claims the arbitration process is an expensive failure.
The Anatomy of the $22.4 Billion Estimate
The Health Affairs analysis posits that the IDR process is a fiscal drain, citing $22.4 billion in “total costs.” The authors categorize $15.6 billion of this figure as “payment amounts”—specifically, IDR awards that exceeded the insurer-calculated QPA.
The QPA Controversy
The QPA serves as the median in-network rate paid for a service in a specific region during 2019, adjusted for inflation. However, providers have long argued that the QPA is a “black box.” Insurers calculate these figures internally with little oversight or transparency.
Recent legal challenges have added weight to these concerns. The Fifth Circuit Court of Appeals recently vacated portions of the methodology used to calculate the QPA, finding that insurers were effectively using the loophole to artificially suppress payments. When the Health Affairs study treats the QPA—or even 200% of the QPA—as the "correct" baseline, it assumes a benchmark that may be fundamentally disconnected from the actual cost of providing care.
The Missing Ledger: Why the Analysis Is One-Sided
The primary criticism leveled against the recent analysis is its failure to account for the “other side of the ledger.” While the report meticulously tracks the costs of the 6% of claims that enter the IDR process, it ignores the 94% of claims that are either settled through open negotiation or paid at the initial rate.
The "Hidden" Savings
The Congressional Budget Office (CBO) originally projected that the NSA would reduce overall healthcare spending. Government Accountability Office (GAO) data and reports from the Department of Health and Human Services (HHS) have corroborated this, showing a distinct downward trend in both in-network reimbursement rates and out-of-network out-of-pocket costs for patients.
If the Health Affairs methodology were applied to a hypothetical scenario where every single claim was settled at a low initial rate, the study would still report that the law saved nothing. By excluding the massive volume of claims that never reach arbitration—where payments are often significantly lower than pre-NSA levels—the analysis creates a skewed narrative. It focuses on the “noise” of high-dollar, rare disputes while ignoring the “signal” of systemic cost reduction across the broader healthcare market.
High-Dollar Outliers vs. Systemic Reality
The analysis draws heavily on headline-grabbing cases, such as breast reduction surgeries with arbitration awards 80 times higher than Medicare rates. While these cases are technically accurate data points, they represent a statistically insignificant 0.4% of total awards.
Conversely, the data also contains thousands of claims where insurers offered payments of as little as a penny or a nickel for complex, life-saving procedures. A balanced analysis would acknowledge both extremes. By fixating on the high-dollar anomalies, the report risks promoting policies that punish the entire provider community for the actions of a tiny minority, without addressing the predatory insurer practices—such as “shared savings” arrangements—that actually drive providers into the IDR process in the first place.
Implications for Healthcare Affordability
The debate is not merely academic; it has profound implications for patient access. A recent Gallup poll revealed that American access to affordable healthcare is at a five-year low. If policymakers rely on incomplete data to "fix" the IDR process, they risk exacerbating this crisis.
The Proposed Path Forward
For those working within the system, the solution to rising costs is not to dismantle the arbitration process but to bring transparency and fairness to the underlying incentives:
- Auditing the QPA: Standardizing how the median rate is calculated and ensuring it reflects actual market conditions.
- Addressing “Shared Savings”: Curbing financial arrangements that incentivize insurers to underpay providers, which forces providers to seek arbitration as a last resort.
- Timely Payments: Enforcing the actual payout of IDR awards. Currently, many providers win their disputes but find that the “awards” exist only on paper, as insurers delay or deny payment.
Conclusion: Toward Honest Accounting
The conversation surrounding the No Surprises Act is far too important to be built on incomplete data. When researchers and policymakers omit the billions saved through initial payment reductions and focus exclusively on the costs of dispute resolution, they fail to provide an accurate picture of the law’s success.
To improve the affordability of the U.S. healthcare system, we must move beyond the current binary debate. We need a nuanced, transparent, and honest accounting that recognizes both the necessity of patient protections and the economic realities of the providers who deliver the care. Only by looking at the entire ledger—the savings and the costs alike—can we craft policies that ensure the No Surprises Act remains a tool for patient protection rather than a source of systemic dysfunction.
